Lineage Cell Therapeutics Inc (LCTX) — Cash Flow-to-Debt Ratio
Lineage Cell Therapeutics Inc (LCTX) has a Cash Flow-to-Debt Ratio of -0.05x as of September 2025, meaning its operating cash flow of $-3.62 Million could theoretically repay 0% of its total liabilities ($68.84 Million) in one year. See Lineage Cell Therapeutics Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Lineage Cell Therapeutics Inc Cash Flow-to-Debt Ratio (1991–2024)
Historical debt coverage capacity for Lineage Cell Therapeutics Inc across 34 annual periods. Also explore Lineage Cell Therapeutics Inc (LCTX) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Lineage Cell Therapeutics Inc (1991–2024)
Year-by-year debt coverage analysis for Lineage Cell Therapeutics Inc. For market capitalisation and broader financial context, see LCTX market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.64x | $-23.09 Million | $36.21 Million | ▲ +12.9% |
| 2023 | -0.73x | $-28.57 Million | $39.00 Million | ▼ -3678.2% |
| 2022 | 0.02x | $1.06 Million | $51.73 Million | ▲ +107.3% |
| 2021 | -0.28x | $-23.56 Million | $83.65 Million | ▲ +81.7% |
| 2020 | -1.54x | $-19.75 Million | $12.82 Million | ▲ +31.4% |
| 2019 | -2.24x | $-31.95 Million | $14.23 Million | ▲ +31.6% |
| 2018 | -3.28x | $-30.88 Million | $9.41 Million | ▲ +3.5% |
| 2017 | -3.40x | $-30.52 Million | $8.98 Million | ▲ +3.1% |
| 2016 | -3.51x | $-42.33 Million | $12.06 Million | ▼ -43.5% |
| 2015 | -2.45x | $-44.54 Million | $18.21 Million | ▲ +23.3% |
| 2014 | -3.19x | $-38.85 Million | $12.18 Million | ▼ -67.2% |
| 2013 | -1.91x | $-29.51 Million | $15.47 Million | ▲ +47.1% |
| 2012 | -3.61x | $-19.68 Million | $5.45 Million | ▼ -16.0% |
| 2011 | -3.11x | $-13.59 Million | $4.37 Million | ▼ -54.7% |
| 2010 | -2.01x | $-7.73 Million | $3.85 Million | ▼ -12.6% |
| 2009 | -1.79x | $-4.26 Million | $2.39 Million | ▼ -499.0% |
| 2008 | -0.30x | $-1.60 Million | $5.38 Million | ▲ +22.6% |
| 2007 | -0.38x | $-1.24 Million | $3.22 Million | ▲ +23.3% |
| 2006 | -0.50x | $-1.26 Million | $2.52 Million | ▲ +23.5% |
| 2005 | -0.66x | $-1.41 Million | $2.16 Million | ▲ +49.8% |
| 2004 | -1.31x | $-1.54 Million | $1.18 Million | ▼ -599.1% |
| 2003 | -0.19x | $-654.14K | $3.50 Million | ▲ +76.6% |
| 2002 | -0.80x | $-2.13 Million | $2.67 Million | ▲ +49.3% |
| 2001 | -1.57x | $-3.21 Million | $2.04 Million | ▲ +88.3% |
| 2000 | -13.50x | $-4.86 Million | $359.75K | ▼ -82.9% |
| 1999 | -7.38x | $-4.39 Million | $595.51K | ▼ -40.6% |
| 1998 | -5.25x | $-2.10 Million | $400.00K | ▼ -626.9% |
| 1997 | -0.72x | $-1.30 Million | $1.80 Million | ▲ +93.1% |
| 1996 | -10.50x | $-2.10 Million | $200.00K | ▲ +0.0% |
| 1995 | -10.50x | $-2.10 Million | $200.00K | ▼ -110.0% |
| 1994 | -5.00x | $-2.00 Million | $400.00K | ▲ +68.8% |
| 1993 | -16.00x | $-1.60 Million | $100.00K | ▼ -23.1% |
| 1992 | -13.00x | $-1.30 Million | $100.00K | ▼ -333.3% |
| 1991 | -3.00x | $-600.00K | $200.00K | — |